Adam Levysohn is the Global Head of Biogen’s Biosimilars Business Unit (BBU) Value and Access team. He has more than 16 years of industry experience in value and access roles spanning multiple therapeutic areas. He has previously helped build and lead market access functions in a number of companies including Novo Nordisk, Novartis and Takeda. In addition to pricing, reimbursement, tenders and contracting, Adam and his team at Biogen have focused on establishing gain sharing programs across Europe in partnerships with health care providers, national and regional authorities and hospital pharmacists.
Conference Keynote Speaker